Advanced search
Publication Cover
Future Medicinal Chemistry Volume 7, 2015 - Issue 16
Submit an article Journal homepage
667
Views
2
CrossRef citations to date
0
Altmetric
Review

Protein–Protein Interactions as Drug Targets

Malgorzata Skwarczynska1 Lead Discovery Center GmbH, 44227Dortmund, GermanyView further author information
&
Christian Ottmann2 Laboratory of Chemical Biology & Institute of Complex Molecular Systems, Department of Biomedical Engineering, Technische Universiteit Eindhoven, Den Dolech 2, 5612AZ Eindhoven, The Netherlands;3 Department of Chemistry, University of Duisburg-Essen, Universitätsstrasse 7, 45117Essen, GermanyCorrespondence[email protected]
View further author information
Pages 2195-2219 | Published online: 29 Oct 2015

References

  • Milroy L-G , GrossmannTN, HennigS, BrunsveldL, OttmannC. Modulators of protein–protein interactions. Chem. Rev.114, 4695–4748 (2014).
  • Arkin MR , TangY, WellsJA. Small-molecule inhibitors of protein–protein interactions: progressing toward the reality. Chem. Biol.21 (9), 1102–1114 (2014).
  • Kuenemann MA , SperandioO, LabbéCM, LagorceD, MitevaMA, VilloutreixBO. In silico design of low molecular weight protein–protein interaction inhibitors: overall concept and recent advances. Prog. Biophys. Mol. Biol. doi:10.1016/j.pbiomolbio.2015.02.006 (2015) ( Epub ahead of print).
  • Laraia L , McKenzieG, SpringDR, VenkitaramanAR, HugginsDJ. Overcoming chemical, biological, and computational challenges in the development of inhibitors targeting protein–protein interactions. Chem. Biol.22 (6), 689–703 (2015).
  • Venkatesan K , RualJ, VazquezAet al. An empirical framework for binary interactome mapping. Nat. Methods6 (1), 83–90 (2008).
  • Stumpf M , ThorneT, de SilvaEet al. Estimating the size of the human interactome. Proc. Natl Acad. Sci. USA105, 6959–6964 (2008).
  • Zhang QC , PetreyD, DengLet al. Structure-based prediction of protein–protein interactions on a genome-wide scale. Nature490 (7421), 556–560 (2012).
  • Tse C , ShoemakerAR, AdickesJet al. ABT-263: a potent and orally bioavailable Bcl-2 family inhibitor. Cancer Res.68 (9), 3421–3428 (2008).
  • Cleary JM , LimaCMSR, HurwitzHIet al. A Phase I clinical trial of navitoclax, a targeted high-affinity Bcl-2 family inhibitor, in combination with gemcitabine in patients with solid tumors. Invest. New Drugs32, 937–945 (2014).
  • Vassilev LT , VuBT, GravesBet al. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science303 (5659), 844–848 (2004).
  • Biswas S , KillickE. The clinical development of p53-reactivating drugs in sarcomas-charting future therapeutic approaches and understanding the clinical molecular toxicology of nutlins. Expert Opin. Investig. Drugs23 (5), 692–645 (2014).
  • Filippakopoulos P , KnappS. Targeting bromodomains: epigenetic readers of lysine acetylation. Nat. Rev. Drug Discov.13 (5), 337–356 (2014).
  • Higueruelo AP , JubbH, BlundellTL. Protein-protein interactions as druggable targets: recent technological advances. Curr. Opin. Pharmacol.13 (5), 791–796 (2013).
  • Uvebrant K , da Graça ThrigeD, RosénAet al. Discovery of selective small-molecule CD80 inhibitors. J. Biomol. Screen.12 (4), 464–472 (2007).
  • Sun H , LuJ, LiuLet al. Nonpeptidic and potent small-molecule inhibitors of cIAP-1/2 and XIAP proteins. J. Med. Chem.53 (17), 6361–6367 (2010).
  • Kwon HS , KimD-R, YangEGet al. Inhibition of VEGF transcription through blockade of the hypoxia inducible factor-1α-p300 interaction by a small molecule. Bioorg. Med. Chem. Lett.22 (16), 5249–5252 (2012).
  • Molzan M , KasperS, RöglinLet al. Stabilization of physical RAF/14–3–3 interaction by cotylenin A as treatment strategy for RAS mutant cancers. ACS Chem. Biol.8, 1869–1875 (2013).
  • Ottmann C , WeyandM, SassaTet al. A structural rationale for selective stabilization of anti-tumor interactions of 14–3–3 proteins by cotylenin A. J. Mol. Biol.386 (4), 913–919 (2009).
  • Thiel P , KaiserM, OttmannC. Small-molecule stabilization of protein–protein interactions: an underestimated concept in drug discovery?Angew. Chem. Int. Ed. Engl.51 (9), 2012–2018 (2012).
  • Jin L , WangW, FangG. Targeting protein–protein interaction by small molecules. Annu. Rev. Pharmacol. Toxicol.54, 435–456 (2014).
  • Bier D , ThielP, BrielsJ, OttmannC. Stabilization of protein–protein interactions in chemical biology and drug discovery. Prog. Biophys. Mol. Biol. doi:10.1016/j.pbiomolbio.2015.05.002 (2015) ( Epub ahead of print).
  • Allen JG , BourbeauMP, WohlhieterGEet al. Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein–protein interaction. J. Med. Chem.52 (22), 7044–7053 (2009).
  • Koblish HK , ZhaoS, FranksCFet al. Benzodiazepinedione inhibitors of the Hdm2:p53 complex suppress human tumor cell proliferation in vitro and sensitize tumors to doxorubicin in vivo. Mol. Cancer Ther.5 (1), 160–169 (2006).
  • Shangary S , QinD, McEachernDet al. Temporal activation of p53 by a specific MDM2 inhibitor is selectively toxic to tumors and leads to complete tumor growth inhibition. Proc. Natl Acad. Sci. USA105 (10), 3933–3938 (2008).
  • Czarna A , BeckB, SrivastavaSet al. Robust generation of lead compounds for protein–protein interactions by computational and MCR chemistry: p53/Hdm2 antagonists. Angew. Chem. Int. Ed. Engl.49 (31), 5352–5356 (2010).
  • Davey DD , AdlerM, ArnaizDet al. Design, synthesis, and activity of 2-imidazol-1-ylpyrimidine derived inducible nitric oxide synthase dimerization inhibitors. J. Med. Chem.50 (6), 1146–1157 (2007).
  • Chu G-H , Le BourdonnecB, GuMet al. Design and synthesis of imidazopyrimidine derivatives as potent iNOS dimerization inhibitors. Open Med Chem J.3, 8–13 (2009).
  • Ohtsuka M , KonnoF, HondaHet al. PPA250 [3-(2,4-Difluorophenyl)-6-{2-[4-(1H-imidazol-1-ylmethyl) phenoxy] ethoxy}-2-phenylpyridine], a novel orally effective inhibitor of the dimerization of inducible nitric-oxide synthase, exhibits an anti-inflammatory effect in animal models of chronic. J. Pharmacol. Exp. Ther.303 (1), 52–57 (2002).
  • Erbe DV , WangS, XingY, TobinJF. Small molecule ligands define a binding site on the immune regulatory protein B7.1. J. Biol. Chem.277 (9), 7363–7368 (2002).
  • Yoakim C , OgilvieWW, GoudreauNet al. Discovery of the first series of inhibitors of human papillomavirus type 11: inhibition of the assembly of the E1–E2–Origin DNA complex. Bioorg. Med. Chem. Lett.13 (15), 2539–2541 (2003).
  • Deng Y , ShippsGW, ZhaoLet al. Modulating the interaction between CDK2 and cyclin A with a quinoline-based inhibitor. Bioorg. Med. Chem. Lett.24 (1), 199–203 (2014).
  • Benicchi T , IozziS, SvahnAet al. A homogeneous HTRF assay for the identification of inhibitors of the TWEAK-Fn14 protein interaction. J. Biomol. Screen.17 (7), 933–945 (2012).
  • Kenny CH , DingW, KelleherKet al. Development of a fluorescence polarization assay to screen for inhibitors of the FtsZ/ZipA interaction. Anal. Biochem.323 (2), 224–233 (2003).
  • Von Kleist L , StahlschmidtW, BulutHet al. Role of the clathrin terminal domain in regulating coated pit dynamics revealed by small molecule inhibition. Cell146 (3), 471–484 (2011).
  • Moerke NJ , AktasH, ChenHet al. Small-molecule inhibition of the interaction between the translation initiation factors eIF4E and eIF4G. Cell128 (2), 257–267 (2007).
  • Papadopoulos E , JenniS, KabhaEet al. Structure of the eukaryotic translation initiation factor eIF4E in complex with 4EGI-1 reveals an allosteric mechanism for dissociating eIF4G. Proc. Natl Acad. Sci. USA111 (31), E3187–E3195 (2014).
  • Mehraein-Ghomi F , KegelSJ, ChurchDRet al. Targeting androgen receptor and JunD interaction for prevention of prostate cancer progression. Prostate74 (7), 792–803 (2014).
  • Miyata Y , ChangL, BainorAet al. High-throughput screen for Escherichia coli heat shock protein 70 (Hsp70/DnaK): ATPase assay in low volume by exploiting energy transfer. J. Biomol. Screen.15 (10), 1211–1219 (2010).
  • Wisén S , BertelsenE, ThompsonAet al. Binding of a small molecule at a protein–protein interface regulates the chaperone activity of hsp70–hsp40. ACS Chem. Biol.5 (6), 611–622 (2010).
  • Zimmermann G , PapkeB, IsmailSet al. Small molecule inhibition of the KRAS-PDEδ interaction impairs oncogenic KRAS signalling. Nature497 (7451), 638–642 (2013).
  • Gautier B , MitevaM a, GoncalvesVet al. Targeting the proangiogenic VEGF-VEGFR protein–protein interface with drug-like compounds by in silico and in vitro screening. Chem. Biol.18 (12), 1631–1639 (2011).
  • Chen Z , RuanQ, HanSet al. Discovery of structure-based small molecular inhibitor of αB-crystallin against basal-like/triple-negative breast cancer development in vitro and in vivo. Breast Cancer Res. Treat.145 (1), 45–59 (2014).
  • Starzec A , MitevaMA, LadamP, VilloutreixBO, PerretGY. Discovery of novel inhibitors of vascular endothelial growth factor-A-Neuropilin-1 interaction by structure-based virtual screening. Bioorg. Med. Chem.22 (15), 4042–4048 (2014).
  • Liu W-Q , MegaleV, BorrielloLet al. Synthesis and structure–activity relationship of non-peptidic antagonists of neuropilin-1 receptor. Bioorg. Med. Chem. Lett.24 (17), 4254–4259 (2014).
  • Wang G , WangX, YuHet al. Small-molecule activation of the TRAIL receptor DR5 in human cancer cells. Nat. Chem. Biol.9 (2), 84–89 (2013).
  • Song Y , Margolles-ClarkE, BayerA, BuchwaldP. Small-molecule modulators of the OX40-OX40 ligand co-stimulatory protein–protein interaction. Br. J. Pharmacol.117 (21), 4955–4969 (2014).
  • Rose R , ErdmannS, BovensSet al. Identification and structure of small-molecule stabilizers of 14–3–3 protein–protein interactions. Angew. Chem. Int. Ed. Engl.49 (24), 4129–4132 (2010).
  • Graves B , ThompsonT, XiaMet al. Activation of the p53 pathway by small-molecule-induced MDM2 and MDMX dimerization. Proc. Natl Acad. Sci. USA109 (29), 11788–11793 (2012).
  • Malashkevich VN , DulyaninovaNG, RamagopalUAet al. Phenothiazines inhibit S100A4 function by inducing protein oligomerization. Proc. Natl Acad. Sci. USA107 (19), 8605–8610 (2010).
  • Gerritz SW , CianciC, KimSet al. Inhibition of influenza virus replication via small molecules that induce the formation of higher-order nucleoprotein oligomers. Proc. Natl Acad. Sci. USA108 (37), 15366–15371 (2011).
  • Classen S , OllandS, BergerJ. Structure of the topoisomerase II ATPase region and its mechanism of inhibition by the chemotherapeutic agent ICRF-187. Proc. Natl Acad. Sci. USA100 (19), 543–549 (2003).
  • Bulawa CE , ConnellyS, DevitMet al. Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc. Natl Acad. Sci. USA109 (24), 9629–9634 (2012).
  • Zhang M , PascalJM, ZhangJ-F. Unstructured to structured transition of an intrinsically disordered protein peptide in coupling Ca2+-sensing and SK channel activation. Proc. Natl Acad. Sci. USA110 (12), 4828–4833 (2013).
  • Jose RA , VoetA, BroosKet al. An integrated fragment based screening approach for the discovery of small molecule modulators of the VWF-GPIbα interaction. Chem. Commun. (Camb.)48 (92), 11349–11351 (2012).
  • Villoutreix BO , LabbéC, LagorceD, LacondeG, SperandioO. A leap into the chemical space of protein–protein interaction inhibitors. Curr. Pharm. Des.18 (30), 4648–4667 (2012).
  • Metz A , CigliaE, GohlkeH. Modulating protein–protein interactions: from structural determinants of binding to druggability prediction to application. Curr. Pharm. Des.18 (30), 4630–4647 (2012).
  • Aeluri M , ChamakuriS, DasariBet al. Small molecule modulators of protein–protein interactions: selected case studies. Chem. Rev.114 (9), 4640–4694 (2014).
  • Griffith OW , StuehrDJ. Nitric oxide synthases: properties and catalytic mechanism. Annu. Rev. Physiol.57, 707–736 (1995).
  • Stuehr DJ . Mammalian nitric oxide synthases. Biochim. Biophys. Acta1411 (2–3), 217–230 (1999).
  • O'dell T , HuangP, DawsonTet al. Endothelial NOS and the blockade of LTP by NOS inhibitors in mice lacking neuronal NOS. Science265, 542–546 (1994).
  • Moncada S , HiggsE. Molecular mechanisms and therapeutic strategies related to nitric oxide. FASEB J.9, 1319–1330 (1995).
  • Kröncke K , FehselK, Kolb-BachofenV. Inducible nitric oxide synthase and its product nitric oxide, a small molecule with complex biological activities. Biol. Chem. Hoppe Seyler376 (6), 327–343 (1995).
  • Ghosh DK , StuehrDJ. Macrophage NO synthase: characterization of isolated oxygenase and reductase domains reveals a head-to-head subunit interaction. Biochemistry34 (3), 801–807 (1995).
  • Alderton WK , CooperCE, KnowlesRG. Nitric oxide synthases: structure, function and inhibition. Biochem. J.357 (Pt 3), 593–615 (2001).
  • Siddhanta U , PrestaA, FanB, WolanD, RousseauDL, StuehrDJ. Domain swapping in inducible nitric-oxide synthase: elektron transfer occurs between flavin and heme groups located on adjecent subjunits in the dimer domain. J. Biol. Chem.273, 18950–18958 (1998).
  • Vallance P , LeiperJ. Blocking NO synthesis: how, where and why?Nat. Rev. Drug Discov.1 (12), 939–950 (2002).
  • Bryk R , WolffD. Mechanism of inducible nitric oxide synthase inactivation by aminoguanidine and L-N6-(1-Iminoethyl)lysine. Biochemistry37 (97), 4844–4852 (1998).
  • Edwards RM , StackEJ, TriznaW. Interaction of l-arginine analogs with l-arginine uptake in rat renal brush border membrane vesicles. J. Pharmacol. Exp. Ther.285 (3), 1019–1022 (1998).
  • Sennequier N , WolanD, StuehrD. Antifungal imidazoles block assembly of inducible NO synthase into an active dimer. J. Biol. Chem.274 (2), 930–938 (1999).
  • McMillan K , AdlerM, AuldDSet al. Allosteric inhibitors of inducible nitric oxide synthase dimerization discovered via combinatorial chemistry. Proc. Natl Acad. Sci. USA97 (4), 1506–1511 (2000).
  • Sohn M-J , HurG-M, ByunH-S, KimW-G. Cyclo(dehydrohistidyl-l-tryptophyl) inhibits nitric oxide production by preventing the dimerization of inducible nitric oxide synthase. Biochem. Pharmacol.75 (4), 923–930 (2008).
  • Zhang W , RamamoorthyY, KilicarslanT, NolteH, TyndaleR, SellersE. Inhibition of cytochromes P450 by antifungal imidazole derivatives. Drug Metab. Dispos.30 (3), 314–318 (2002).
  • Bonnefous C , PayneJE, RoppeJet al. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. J. Med. Chem.52 (9), 3047–3062 (2009).
  • Symons KT , MassariME, NguyenPMet al. KLYP956 Is a non-imidazole-based orally active inhibitor of nitric-oxide synthase dimerization. Mol. Pharmacol.76 (1), 153–162 (2009).
  • Nagpal L , HaqueMM, SahaAet al. Mechanism of inducible nitric-oxide synthase dimerization inhibition by novel pyrimidine imidazoles. J. Biol. Chem.288 (27), 19685–19697 (2013).
  • Harris ES , McIntyreTM, PrescottSM, ZimmermanGA. The leukocyte integrins. J. Biol. Chem.275 (31), 23409–23412 (2000).
  • Reilly P , WoskaJJ, JeanfavreD, McNallyE, RothleinR, BormannB. The native structure of intercellular adhesion molecule-1 (ICAM-1) is a dimer. Correlation with binding to LFA-1. J. Immunol.155, 529–532 (1995).
  • Butcher EC . Leukocyte-endothelial cell recognition: three (or more) steps to specificity and diversity. Cell67, 1033–1036 (1991).
  • Grakoui A . The immunological synapse: a molecular machine controlling T cell activation. Science285 (5425), 221–227 (1999).
  • Shimaoka M , SpringerTA. Therapeutic antagonists and the conformational regulation of the β2 integrins. Curr. Top. Med. Chem.4, 1485–1495 (2004).
  • Yonekawa K , HarlanJM. Targeting leukocyte integrins in human diseases. Exp. Cell. Res.77, 129–140 (2005).
  • Miele M , BennettC, MillerB, WelchD. Enhanced metastativ ability of TNF-α-treated malighangt melanoma cells is reduced by intercellular adhesion molecule-1 (ICAM-1, CD54) antisense oligonucleotides. Exp. Cell. Res.214, 231–241 (1994).
  • Cather JC , CatherJC, MenterA. Modulating T cell responses for the treatment of psoriasis: a focus on efalizumab. Expert Opin. Biol. Ther.3 (2), 361–370 (2003).
  • Gauvreau GM , BeckerAB, BouletL-Pet al. The effects of an anti-CD11a mAb, efalizumab, on allergen-induced airway responses and airway inflammation in subjects with atopic asthma. J. Allergy Clin. Immunol.112 (2), 331–338 (2003).
  • Zimmerman T , BlancoFJ. Inhibitors targeting the LFA-1/ICAM-1 cell-adhesion interaction: design and mechanism of action. Curr. Pharm. Des.14 (22), 2128–2139 (2008).
  • Kallen J , WelzenbachK, RamagePet al. Structural basis for LFA-1 inhibition upon lovastatin binding to the CD11a I-domain. J. Mol. Biol.292 (1), 1–9 (1999).
  • Weitz-Schmidt G , WelzenbachK, DawsonJ, KallenJ. Improved lymphocyte function-associated antigen-1 (LFA-1) inhibition by statin derivatives: molecular basis determined by x-ray analysis and monitoring of LFA-1 conformational changes in vitro and ex vivo. J. Biol. Chem.279 (45), 46764–47771 (2004).
  • Kelly TA , JeanfavreDD, McNeilDWet al. Cutting edge: a small molecule antagonist of LFA-1-mediated cell adhesion. J. Immunol.163 (10), 5173–5177 (1999).
  • Last-Barney K , DavidsonW, CardozoMet al. Binding site elucidation of hydantoin-based antagonists of LFA-1 using multidisciplinary technologies: evidence for the allosteric inhibition of a protein–protein interaction. J Am Chem Soc.123 (24), 5643–5650 (2001).
  • Wu J-P , EmeighJ, GaoD aet al. Second-generation lymphocyte function-associated antigen-1 inhibitors: 1H-imidazo[1,2-alpha]imidazol-2-one derivatives. J. Med. Chem.47 (22), 5356–5366 (2004).
  • Panzenbeck MJ , JeanfavreDD, KellyT aet al. An orally active, primate selective antagonist of LFA-1 inhibits delayed-type hypersensitivity in a humanized-mouse model. Eur. J. Pharmacol.534 (1–3), 233–240 (2006).
  • Potin D , LaunayM, NicolaiEet al. De novo design, synthesis, and in vitro activity of LFA-1 antagonists based on a bicyclic[5.5]hydantoin scaffold. Bioorg. Med. Chem. Lett.15 (4), 1161–1164 (2005).
  • Dodd DS , SheriffS, ChangCJet al. Design of LFA-1 antagonists based on a 2,3-dihydro-1H-pyrrolizin-5(7aH)-one scaffold. Bioorg. Med. Chem. Lett.17 (7), 1908–1911 (2007).
  • Potin D , LaunayM, MonatlikFet al. Discovery and development of 5-[(5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]non- 7-yl-methyl]-3-thiophenecarboxylic Acid (BMS-587101)-A small molecule antagonist of leukocyte function associated antigen-1. J. Med. Chem.49, 6946–6949 (2006).
  • Watterson SH , XiaoZ, DoddDSet al. Small molecule antagonist of leukocyte function associated antigen-1 (LFA-1): structure–activity relationships leading to the identification of 6-((5S,9R)-9-(4-cyanophenyl)-3-(3,5-dichlorophenyl)-1-methyl-2,4-dioxo-1,3,7-triazaspiro[4.4]nonan-7-yl)nicotin. J. Med. Chem.53 (9), 3814–3830 (2010).
  • Wattanasin S , AlbertR, EhrhardtCet al. 1,4-Diazepane-2-ones as novel inhibitors of LFA-1. Bioorg. Med. Chem. Lett.13 (3), 499–502 (2003).
  • Wattanasin S , KallenJ, MyersSet al. 1,4-Diazepane-2,5-diones as novel inhibitors of LFA-1. Bioorg. Med. Chem. Lett.15 (4), 1217–1220 (2005).
  • Liu G , LinkJT, PeiZet al. Discovery of novel p-Arylthio cinnamides as antagonists of leukocyte identification of an additional binding pocket based on an anilino diaryl sulfide lead. J. Med. Chem.43, 4025–4040 (2000).
  • Winn M , ReillyEB, LiuGet al. Discovery of Nnovel p-Arylthio cinnamides as antagonists of leukocyte structure–activity relationship of substituents on the benzene ring of the cinnamide. J. Med. Chem.44 (Scheme 4), 4393–4403 (2001).
  • Guckian KM , LinEY-S, SilvianL, FriedmanJE, ChinD, ScottDM. Design and synthesis of a series of meta aniline-based LFA-1 ICAM inhibitors. Bioorg. Med. Chem. Lett.18 (19), 5249–5251 (2008).
  • Lin EY-S , GuckianKM, SilvianLet al. Structure–activity relationship of ortho- and meta-phenol based LFA-1 ICAM inhibitors. Bioorg. Med. Chem. Lett.18 (19), 5245–5248 (2008).
  • Shoda M , HaradaT, YanoKet al. Virtual screening leads to the discovery of an effective antagonist of lymphocyte function-associated antigen-1. ChemMedChem2 (4), 515–521 (2007).
  • Gadek TR , BurdickDJ, McDowellRSet al. Generation of an LFA-1 antagonist by the transfer of the ICAM-1 immunoregulatory epitope to a small molecule. Science295 (5557), 1086–9 (2002).
  • San Sebastián E , ZimmermanT, ZubiaAet al. Design, synthesis, and functional evaluation of leukocyte function associated antigen-1 antagonists in early and late stages of cancer development. J. Med. Chem.56, 735–747 (2013).
  • Kollmann CS , BaiX, TsaiC-Het al. Application of encoded library technology (ELT) to a protein–protein interaction target: discovery of a potent class of integrin lymphocyte function-associated antigen 1 (LFA-1) antagonists. Bioorg. Med. Chem.22 (7), 2353–2365 (2014).
  • Hintersteiner M , KallenJ, SchmiedMet al. Identification and X-ray co-crystal structure of a small-molecule activator of LFA-1-ICAM-1 binding. Angew. Chem. Int. Ed. Engl.53 (17), 4322–4326 (2014).
  • Zarbock A , KempfT, WollertKC, VestweberD. Leukocyte integrin activation and deactivation: novel mechanisms of balancing inflammation. J. Mol. Med. (Berl.).90 (4), 353–359 (2012).
  • Gardino A , YaffeM. 14–3–3 proteins as signaling integration points for cell cycle control and apoptosis. Semin. Cell. Dev. Biol.22 (7), 688–695 (2011).
  • Robinson DN . 14–3–3, an integrator of cell mechanics and cytokinesis. Small GTPases1 (3), 165–169 (2010).
  • Messaritou G , GrammenoudiS, SkoulakisEMC. Dimerization is essential for 14–3–3zeta stability and function in vivo. J. Biol. Chem.285 (3), 1692–1700 (2010).
  • Morton DG , ShakesDC, NugentSet al. The caenorhabditis elegans par-5 gene encodes a 14–3–3 protein required for cellular asymmetry in the early embryo. Dev. Biol.241 (1), 47–58 (2002).
  • Aitken A . 14–3–3 proteins: a historic overview. Semin. Cancer Biol.16 (3), 162–172 (2006).
  • De Boer AH , van KleeffPJM, GaoJ. Plant 14–3–3 proteins as spiders in a web of phosphorylation. Protoplasma250 (2), 425–440 (2013).
  • Bridges D , MoorheadGBG. 14–3–3 proteins: a number of functions for a numbered protein. Sci STKE.2005 (296), re10 (2005).
  • Yaffe M , RittingerK, VoliniaSet al. The structural basis for 14–3–3: phosphopeptide binding specificity. Cell91, 961–971 (1997).
  • Coblitz B , WuM, ShikanoS, LiM. C-terminal binding: an expanded repertoire and function of 14–3–3 proteins. FEBS Lett.580 (6), 1531–1535 (2006).
  • Johnson C , CrowtherS, StaffordMJ, CampbellDG, TothR, MacKintoshC. Bioinformatic and experimental survey of 14–3–3-binding sites. Biochem. J.427 (1), 69–78 (2010).
  • Vassilev A , KanekoK, ShuH, ZhaoY, DePamphilisM. TEAD/TEF transcription factors utilize the activation domain of YAP65, a Src/Yes-associated protein localized in the cytoplasm. Genes Dev.15 (10), 1229–1241 (2001).
  • Schumacher B , SkwarczynskaM, RoseR, OttmannC. Structure of a 14–3–3σ-YAP phosphopeptide complex at 1.15 A resolution. Acta Crystallogr. Sect. F. Struct. Biol. Cryst. Commun.66 (Pt 9), 978–984 (2010).
  • Obsilova V , NedbalkovaE, SilhanJet al. The 14–3–3 protein affects the conformation of the regulatory domain of human tyrosine hydroxylase. Biochemistry47 (6), 1768–1777 (2008).
  • Dumaz N , MaraisR. Protein kinase A blocks Raf-1 activity by stimulating 14–3–3 binding and blocking Raf-1 interaction with RAS. J. Biol. Chem.278 (32), 29819–29823 (2003).
  • Molzan M , OttmannC. Synergistic binding of the phosphorylated S233- and S259-binding sites of C-RAF to one 14–3–3ζ dimer. J. Mol. Biol.423 (4), 486–495 (2012).
  • Liang X , Da PaulaAC, BozókyZet al. Phosphorylation-dependent 14–3–3 protein interactions regulate CFTR biogenesis. Mol. Biol. Cell23 (6), 996–1009 (2012).
  • Johnson C , TintiM, WoodNTet al. Visualization and biochemical analyses of the emerging mammalian 14–3–3-phosphoproteome. Mol Cell Proteomics10 (10), M110.005751 (2011).
  • Freeman A , MorrisonD. 14–3–3 proteins: diverse functions in cell proliferation and cancer progression. Semin. Cell. Dev. Biol.22 (7), 681–687 (2011).
  • Freed E , SymonsM, MacdonaldSG, McCormickF, RuggieriR. Binding of 14–3–3 proteins to the protein kinase Raf and effects on its activation. Science265 (5179), 1713–1716 (1994).
  • Conklin D , GalaktionovK, BeachD. 14–3–3 proteins associate with Cdc25 phosphatases. Proc. Natl Acad. Sci. USA92 (17), 7892–7896 (1995).
  • Rajagopalan S , JaulentAM, WellsM, VeprintsevDB, FershtAR. 14–3–3 activation of DNA binding of p53 by enhancing its association into tetramers. Nucleic Acids Res.36 (18), 5983–5991 (2008).
  • Schumacher B , MondryJ, ThielP, WeyandM, OttmannC. Structure of the p53 C-terminus bound to 14–3–3: implications for stabilization of the p53 tetramer. FEBS Lett.584 (8), 1443–1448 (2010).
  • Basu S , TottyNF, IrwinMS, SudolM, DownwardJ. Akt phosphorylates the Yes-associated protein, YAP, to induce interaction with 14–3–3 and attenuation of p73-mediated apoptosis. Mol. Cell.11 (1), 11–23 (2003).
  • Sluchanko NN , Seit-NebiAS, GusevNB. Phosphorylation of more than one site is required for tight interaction of human tau protein with 14–3–3zeta. FEBS Lett.583 (17), 2739–2742 (2009).
  • Plotegher N , KumarD, TessariIet al. The chaperone-like protein 14–3–3η interacts with human α-synuclein aggregation intermediates rerouting the amyloidogenic pathway and reducing α-synuclein cellular toxicity. Hum. Mol. Genet.23 (21), 5615–5629 (2014).
  • Dzamko N , DeakM, HentatiFet al. Inhibition of LRRK2 kinase activity leads to dephosphorylation of Ser(910)/Ser(935), disruption of 14–3–3 binding and altered cytoplasmic localization. Biochem. J.430 (3), 405–413 (2010).
  • Sato S , ChibaT, SakataEet al. 14–3–3eta is a novel regulator of parkin ubiquitin ligase. EMBO J.25 (1), 211–221 (2006).
  • Ramm G , LaranceM, GuilhausM, JamesDE. A role for 14–3–3 in insulin-stimulated GLUT4 translocation through its interaction with the RabGAP AS160. J. Biol. Chem.281 (39), 29174–29180 (2006).
  • Pierrat B , ItoM, HinzWet al. Uncoupling proteins 2 and 3 interact with members of the 14.3.3 family. Eur. J. Biochem.267 (9), 2680–2687 (2000).
  • Fu H , CoburnJ, CollierRJ. The eukaryotic host factor that activates exoenzyme S of Pseudomonas aeruginosa is a member of the 14–3–3 protein family. Proc. Natl Acad. Sci. USA90 (6), 2320–2324 (1993).
  • Ottmann C , YasminL, WeyandMet al. Phosphorylation-independent interaction between 14–3–3 and exoenzyme S: from structure to pathogenesis. EMBO J.26 (3), 902–913 (2007).
  • Glas A , BierD, HahneG, RademacherC, OttmannC, GrossmannTN. Constrained peptides with target-adapted cross-links as inhibitors of a pathogenic protein–protein interaction. Angew. Chem. Int. Ed. Engl.53 (9), 2489–2493 (2014).
  • Wilker E , YaffeMB. 14–3–3 proteins – a focus on cancer and human disease. J. Mol. Cell. Cardiol.37 (3), 633–642 (2004).
  • Aitken A , BaxterH, DuboisTet al. Specificity of 14–3–3 isoform dimer interactions and phosphorylation. Biochem. Soc. Trans.30, 351–360 (2002).
  • Mackintosh C . Dynamic interactions between 14–3–3 proteins and phosphoproteins regulate diverse cellular processes. Biochem. J.381 (Pt 2), 329–342 (2004).
  • Zhao J , MeyerkordCL, DuY, KhuriFR, FuH. 14–3–3 proteins as potential therapeutic targets. Semin. Cell. Dev. Biol.22 (7), 705–712 (2011).
  • Zhao J , DuY, HortonJRet al. Discovery and structural characterization of a small molecule 14–3–3 protein–protein interaction inhibitor. Proc. Natl Acad. Sci. USA108 (39), 16212–16216 (2011).
  • Mori M , VignaroliG, BottaM. Small molecules modulation of 14–3–3 protein–protein interactions. Drug Discov. Today Technol.10 (4), e541–e547 (2013).
  • Camoni L , Di LucenteC, ViscontiS, AducciP. The phytotoxin fusicoccin promotes platelet aggregation via 14–3–3-glycoprotein Ib-IX-V interaction. Biochem. J.436 (2), 429–436 (2011).
  • Ottmann C . Small-molecule modulators of 14–3–3 protein–protein interactions. Bioorg. Med. Chem.21, 4058–4062 (2013).
  • Milroy L-G , BrunsveldL, OttmannC. Stabilization and inhibition of protein–protein interactions: the 14–3–3 case study. ACS Chem. Biol.8 (1), 27–35 (2013).
  • Wu H , GeJ, YaoSQ. Microarray-assisted high-throughput identification of a cell-permeable small-molecule binder of 14–3–3 proteins. Angew. Chem. Int. Ed. Engl.49 (37), 6528–6532 (2010).
  • Arrendale A , KimK, ChoiJY, LiW, GeahlenRL, BorchRF. Synthesis of a phosphoserine mimetic prodrug with potent 14–3–3 protein inhibitory activity. Chem. Biol.19 (6), 764–771 (2012).
  • Röglin L , ThielP, KohlbacherO, OttmannC. Covalent attachment of pyridoxal-phosphate derivatives to 14–3–3 proteins. Proc Natl Acad Sci USA.109 (18), E1051–E1053; author reply E1054 (2012).
  • Thiel P , RöglinL, MeissnerN, HennigS, KohlbacherO, OttmannC. Virtual screening and experimental validation reveal novel small-molecule inhibitors of 14–3–3 protein–protein interactions. Chem. Commun. (Camb.)49 (76), 8468–8470 (2013).
  • Corradi V , ManciniM, ManettiF, PettaS, SantucciMA, BottaM. Identification of the first non-peptidic small molecule inhibitor of the c-Abl/14–3–3 protein–protein interactions able to drive sensitive and Imatinib-resistant leukemia cells to apoptosis. Bioorg. Med. Chem. Lett.20 (20), 6133–6137 (2010).
  • Yan Y-M , DaiH-Q, DuYet al. Identification of blapsins A and B as potent small-molecule 14–3–3 inhibitors from the insect Blaps japanensis. Bioorg. Med. Chem. Lett.22 (12), 4179–4181 (2012).
  • Woodcock JM , CoolenC, GoodwinKLet al. Destabilisation of dimeric 14–3–3 proteins as a novel approach to anti-cancer therapeutics. Oncotarget.6 (16), 14522–14536 (2015).
  • Fullone MR , ViscontiS, MarraM, FoglianoV, AducciP. Fusicoccin effect on the in vitro interaction between plant 14–3–3 proteins and plasma membrane H+-ATPase. J. Biol. Chem.273 (13), 7698–7702 (1998).
  • Ottmann C , MarcoS, JaspertNet al. Structure of a 14–3–3 coordinated hexamer of the plant plasma membrane H+-ATPase by combining X-ray crystallography and electron cryomicroscopy. Mol. Cell.25 (3), 427–440 (2007).
  • Richter A , RoseR, HedbergC, WaldmannH, OttmannC. An optimised small-molecule stabiliser of the 14–3–3-PMA2 protein–protein interaction. Chemistry18, 6520–6527 (2012).
  • De Vries-van Leeuwen IJ , da Costa PereiraD, FlachKDet al. Interaction of 14–3–3 proteins with the estrogen receptor alpha F domain provides a drug target interface. Proc. Natl Acad. Sci. USA110, 8894–8899 (2013).
  • Anders C , HiguchiY, KoschinskyKet al. A semisynthetic fusicoccane stabilizes a protein–protein interaction and enhances the expression of K+ channels at the cell surface. Chem. Biol.20 (4), 583–593 (2013).
  • Kasukabe T , Okabe-KadoJ, KatoN, SassaT, HonmaY. Effects of combined treatment with rapamycin and cotylenin A, a novel differentiation-inducing agent, on human breast carcinoma MCF-7 cells and xenografts. Breast Cancer Res.7 (6), R1097–R1110 (2005).
  • Jubb H , BlundellTL, AscherDB. Flexibility and small pockets at protein–protein interfaces: new insights into druggability. Prog. Biophys. Mol. Biol. doi:10.1016/j.pbiomolbio.2015.01.009 (2015) ( Epub ahead of print).
  • Dreze M , CharloteauxB, MilsteinSet al. “Edgetic” perturbation of a C. elegans BCL2 ortholog. Nat. Methods6 (11), 843–849 (2009).
  • Zhong Q , SimonisN, LiQ-Ret al. Edgetic perturbation models of human inherited disorders. Mol. Syst. Biol.5, 321 (2009).
  • Sahni N , YiS, ZhongQet al. Edgotype: a fundamental link between genotype and phenotype. Curr. Opin. Genet. Dev.23 (6), 649–657 (2013).
  • Csermely P , KorcsmárosT, KissHJM, LondonG, NussinovR. Structure and dynamics of molecular networks: a novel paradigm of drug discovery: a comprehensive review. Pharmacol. Ther.138 (3), 333–408 (2013).
  • Sahni N , YiS, TaipaleMet al. Widespread macromolecular interaction perturbations in human genetic disorders. Cell161 (3), 647–660 (2015).
  • Watson VG , DrakeKM, PengY, NapperAD. Development of a high-throughput screening-compatible assay for the discovery of inhibitors of the AF4-AF9 interaction using AlphaScreen technology. Assay Drug Dev. Technol.11 (4), 253–268 (2013).
  • Oltersdorf T , ElmoreSW, ShoemakerARet al. An inhibitor of Bcl-2 family proteins induces regression of solid tumours. Nature435 (7042), 677–681 (2005).
  • Vo DD , GautierF, JuinP, GréeR. Structure–activity relationship of selected polyphenol derivatives as inhibitors of Bax/Bcl-xL interaction. Eur. J. Med. Chem.51, 286–293 (2012).
  • Corbel C , WangQ, BousserouelHet al. First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors. Biotechnol. J.6 (7), 860–870 (2011).
  • Margolles-Clark E , Jacques-SilvaMC, GanesanLet al. Suramin inhibits the CD40–CD154 costimulatory interaction: A possible mechanism for immunosuppressive effects. Biochem. Pharmacol.77 (7), 1236–1245 (2009).
  • Margolles-Clark E , KenyonNS, RicordiC, BuchwaldP. Effective and specific inhibition of the CD40-CD154 costimulatory interaction by a naphthalenesulphonic acid derivative. Chem. Biol. Drug Des.76 (4), 305–313 (2010).
  • Silvian L , FriedmanJ, StrauchKet al. Small molecule inhibition of the TNF family cytokine CD40 ligand through a subunit fracture mechanism. ACS Chem. Biol.6 (6), 636–647 (2011).
  • Breuer S , EspinolaS, MorelliX, TorbettBE, AroldST, EngelsIH. A biochemical/biophysical assay Dyad for HTS-compatible triaging of inhibitors of the HIV-1 Nef/Hck SH3 interaction. Curr. Chem. Genomics Transl. Med.7, 16–20 (2013).
  • Thanos CD , DeLanoWL, WellsJA. Hot-spot mimicry of a cytokine receptor by a small molecule. Proc. Natl Acad. Sci. USA103 (42), 15422–15427 (2006).
  • Hu L , MageshS, ChenLet al. Discovery of a small-molecule inhibitor and cellular probe of Keap1–Nrf2 protein–protein interaction. Bioorg. Med. Chem. Lett.23 (10), 3039–3043 (2013).
  • Christ F , VoetA, MarchandAet al. Rational design of small-molecule inhibitors of the LEDGF/p75-integrase interaction and HIV replication. Nat. Chem. Biol.6 (6), 442–448 (2010).
  • Sun Q , BurkeJ, PhanJet al. Discovery of small molecules that bind to K-RAS and inhibit SOS-mediated activation. Angew. Chem. Int. Ed. Engl.51 (25), 6140–6143 (2012).
  • Cianci C , YuK, CombrinkK. Orally active fusion inhibitor of respiratory syncytial virus. Antimicrob. Agents Chemother.48, 413–422 (2004).
  • Andries K , MoeremansM, GeversTet al. Substituted benzimidazoles with nanomolar activity against respiratory syncytial virus. Antivir. Res.60 (3), 209–219 (2003).
  • Ungermannova D , LeeJ, ZhangG, DallmannHG, McHenryCS, LiuX. High-throughput screening AlphaScreen assay for identification of small-molecule inhibitors of ubiquitin E3 ligase SCF(Skp2-Cks1). J. Biomol. Screen.18 (8), 910–920 (2013).
  • Buller F , ZhangY, ScheuermannJ, SchäferJ, BühlmannP, NeriD. Discovery of TNF inhibitors from a DNA-encoded chemical library based on diels-alder cycloaddition. Chem. Biol.16 (10), 1075–1086 (2009).
  • Xie X , SunL, PessettoZYet al. Development of a fluorescence polarization based high-throughput assay to identify Casitas B-lineage lymphoma RING domain regulators. PLoS ONE8 (10), e78042 (2013).
  • Hamdan FF , AudetM, GarneauP, PelletierJ, BouvierM. High-throughput screening of G protein-coupled receptor antagonists using a bioluminescence resonance energy transfer 1-based beta-arrestin2 recruitment assay. J. Biomol. Screen.10 (5), 463–475 (2005).
  • Kao RY , YangD, LauL-Set al. Identification of influenza A nucleoprotein as an antiviral target. Nat. Biotechnol.28 (6), 600–605 (2010).
  • Germain P , GaudonC, PogenbergVet al. Differential action on coregulator interaction defines inverse retinoid agonists and neutral antagonists. Chem. Biol.16 (5), 479–489 (2009).
  • Burns MC , SunQ, DanielsRNet al. Approach for targeting RAS with small molecules that activate SOS-mediated nucleotide exchange. Proc. Natl Acad. Sci. USA111 (9), 3401–3406 (2014).
  • Garrett S , HodgsonL, RybinAet al. A biosensor of S100A4 metastasis factor activation: inhibitor screening and cellular activation dynamics. Biochemistry47 (3), 986–996 (2008).
  • Zhang M , PascalJM, SchumannM, ArmenRS, ZhangJ-F. Identification of the functional binding pocket for compounds targeting small-conductance Ca2-activated potassium channels. Nat. Commun.3, 1021 (2012).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.